Astralis Pharmacy Profile
Key Indicators
- Authorised Capital ₹ 10.15 Cr
as on 21-06-2024
- Paid Up Capital ₹ 5.13 Cr
as on 21-06-2024
- Company Age 17 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 10.35 Cr
as on 21-06-2024
- Revenue 43.32%
(FY 2020)
- Profit 14.59%
(FY 2020)
- Ebitda -4.87%
(FY 2020)
- Net Worth 42.65%
(FY 2020)
- Total Assets 29.72%
(FY 2020)
About Astralis Pharmacy
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.15 Cr and a paid-up capital of Rs 5.13 Cr.
The company has closed loans amounting to ₹10.35 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Neelam Aggarwal and Naman Agarwal serve as directors at the Company.
- CIN/LLPIN
U85195WB2007PTC112572
- Company No.
112572
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jan 2007
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Astralis Pharmacy?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neelam Aggarwal  | Additional Director | 26-Mar-2024 | Current |
| Naman Agarwal | Additional Director | 26-Mar-2024 | Current |
Financial Performance and Corporate Structure Insights of Astralis Pharmacy.
Astralis Pharmacy Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 43.32% increase. The company also saw a substantial improvement in profitability, with a 14.59% increase in profit. The company's net worth Soared by an impressive increase of 42.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Astralis Pharmacy?
In 2020, Astralis Pharmacy had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 23 Nov 2018 | ₹2.60 Cr | Satisfied |
Axis Bank Limited Creation Date: 07 Sep 2017 | ₹3.00 Cr | Satisfied |
Others Creation Date: 24 Dec 2008 | ₹2.25 Cr | Satisfied |
How Many Employees Work at Astralis Pharmacy?
Astralis Pharmacy has a workforce of 4 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Astralis Pharmacy, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Astralis Pharmacy's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
